title: Letters to the editor: comments on the BEAUTIfUL study.
authors.forename: A
authors.initials: A
authors.lastname: Bonny
authors.forename: Id M
authors.initials: IM
authors.lastname: Yitemben
authors.forename: B
authors.initials: B
authors.lastname: Hamdaoui
authors.forename: F
authors.initials: F
authors.lastname: Larrazet
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D001552:Benzazepines / Q000627:therapeutic use*; D002227:Carbazoles / Q000627:therapeutic use; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D000077261:Carvedilol; D003324:Coronary Artery Disease / Q000150:complications / Q000188:drug therapy*; D018450:Disease Progression; D004359:Drug Therapy, Combination; D006801:Humans; D000077550:Ivabradine; D011412:Propanolamines / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D018487:Ventricular Dysfunction, Left / Q000150:complications / Q000188:drug therapy*
chemical_list: D000319:Adrenergic beta-Antagonists; D001552:Benzazepines; D002227:Carbazoles; D002317:Cardiovascular Agents; D011412:Propanolamines; D000077261:Carvedilol; D000077550:Ivabradine